Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e02606-18. doi: 10.1128/AAC.02606-18. Print 2019 Aug.

PMID:
31182534
2.

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution.

Lakota EA, Sato N, Koresawa T, Kondo K, Bhavnani SM, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00267-19. doi: 10.1128/AAC.00267-19. Print 2019 Aug.

PMID:
31182524
3.

Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.

Luna BM, Ershova K, Yan J, Ulhaq A, Nielsen TB, Hsieh S, Pantapalangkoor P, Vanscoy B, Ambrose P, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar EP, Spellberg B.

J Antimicrob Chemother. 2019 Sep 1;74(9):2631-2639. doi: 10.1093/jac/dkz225.

4.

Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.

Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Segura C, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP.

J Glob Antimicrob Resist. 2019 Sep;18:37-44. doi: 10.1016/j.jgar.2019.04.012. Epub 2019 May 30.

PMID:
31154007
5.

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.

McEntee L, Johnson A, Farrington N, Unsworth J, Dane A, Jain A, Cotroneo N, Critchley I, Melnick D, Parr T, Ambrose PG, Das S, Hope W.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00603-19. doi: 10.1128/AAC.00603-19. Print 2019 Aug.

PMID:
31109982
6.

A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England.

Maddison P, Ambrose PA, Sadalage G, Vincent A.

Neuroepidemiology. 2019;53(1-2):93-99. doi: 10.1159/000500268. Epub 2019 May 8.

PMID:
31067543
7.

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, Bhavnani SM.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00318-19. doi: 10.1128/AAC.00318-19. Print 2019 Jun.

PMID:
30962339
8.

False-positive acetylcholine receptor antibody results in patients without myasthenia gravis.

Maddison P, Sadalage G, Ambrose PA, Jacob S, Vincent A.

J Neuroimmunol. 2019 Jul 15;332:69-72. doi: 10.1016/j.jneuroim.2019.04.001. Epub 2019 Apr 3.

PMID:
30959340
9.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.

Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii35-iii41. doi: 10.1093/jac/dkz089.

10.

miR-30e-5p as predictor of generalization in ocular myasthenia gravis.

Sabre L, Maddison P, Wong SH, Sadalage G, Ambrose PA, Plant GT, Punga AR.

Ann Clin Transl Neurol. 2019 Jan 24;6(2):243-251. doi: 10.1002/acn3.692. eCollection 2019 Feb.

11.

Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.

Ambrose PG, VanScoy BD, Luna BM, Yan J, Ulhaq A, Nielsen TB, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar E, Spellberg B.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00112-19. doi: 10.1128/AAC.00112-19. Print 2019 May.

PMID:
30782989
12.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02329-18. doi: 10.1128/AAC.02329-18. Print 2019 Apr.

13.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02372-18. doi: 10.1128/AAC.02372-18. Print 2019 Apr.

14.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

15.

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.

Lepak AJ, Zhao M, Liu Q, Wang P, Wang Y, Bader JC, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02404-18. doi: 10.1128/AAC.02404-18. Print 2019 Mar.

16.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
17.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
18.

Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.

Miglianico M, Eldering M, Slater H, Ferguson N, Ambrose P, Lees RS, Koolen KMJ, Pruzinova K, Jancarova M, Volf P, Koenraadt CJM, Duerr HP, Trevitt G, Yang B, Chatterjee AK, Wisler J, Sturm A, Bousema T, Sauerwein RW, Schultz PG, Tremblay MS, Dechering KJ.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6920-E6926. doi: 10.1073/pnas.1801338115. Epub 2018 Jul 2.

19.

Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.

Sabre L, Maddison P, Sadalage G, Ambrose PA, Punga AR.

J Neuroimmunol. 2018 Aug 15;321:164-170. doi: 10.1016/j.jneuroim.2018.05.003. Epub 2018 May 8.

20.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

21.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

22.

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.

Montero M, VanScoy BD, López-Causapé C, Conde H, Adams J, Segura C, Zamorano L, Oliver A, Horcajada JP, Ambrose PG.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00026-18. doi: 10.1128/AAC.00026-18. Print 2018 May.

23.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):351. doi: 10.1007/s10928-018-9572-2.

PMID:
29446052
24.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Ambrose PG, VanScoy BD, Adams J, Fikes S, Bader JC, Bhavnani SM, Rubino CM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02257-17. doi: 10.1128/AAC.02257-17. Print 2018 Apr.

25.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

26.

Lambert-Eaton myasthenic syndrome and cerebellar ataxia: is Response to immunotherapy a clue to pathogenesis?

Ambrose PA, Maddison P.

Muscle Nerve. 2018 Jan 24. doi: 10.1002/mus.26079. [Epub ahead of print] No abstract available.

PMID:
29365352
27.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Mar 1;73(3):831. doi: 10.1093/jac/dky013. No abstract available.

PMID:
29340605
28.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448. Review. Erratum in: J Antimicrob Chemother. 2018 Mar 1;73(3):831.

PMID:
29304211
29.

Reply to Paul and Leibovici.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Ostrowsky B, Rex JH.

J Infect Dis. 2018 Jan 17;217(3):509-510. doi: 10.1093/infdis/jix537. No abstract available.

PMID:
29240925
30.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

31.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
32.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

33.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

34.

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00630-17. doi: 10.1128/AAC.00630-17. Print 2017 Dec.

35.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

36.

Antibacterial drug development program successes and failures: a pharmacometric explanation.

Ambrose PG.

Curr Opin Pharmacol. 2017 Oct;36:1-7. doi: 10.1016/j.coph.2017.06.002. Epub 2017 Jul 5.

PMID:
28688237
37.

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH; Infectious Diseases Society of America.

J Infect Dis. 2017 Jul 15;216(2):228-236. doi: 10.1093/infdis/jix211. Review.

38.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00476-17. doi: 10.1128/AAC.00476-17. Print 2017 Jun.

39.

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Feb 14;:.

PMID:
28353185
40.

Prevalence of Hepatitis C Screening in an HIV Primary Care Clinic.

Ambrose P, Zepf R, Parrott AH, Dawson-Rose C.

J Assoc Nurses AIDS Care. 2017 May - Jun;28(3):422-427. doi: 10.1016/j.jana.2016.10.008. Epub 2016 Nov 7. No abstract available.

PMID:
27939429
41.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb.

42.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Ambrose PG, VanScoy B, Conde H, McCauley J, Rubino CM, Bhavnani SM.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01605-16. doi: 10.1128/AAC.01605-16. Print 2017 Jan.

43.

Role of Thromboelastography Platelet Mapping and International Normalized Ratio in Defining "Normocoagulability" During Anticoagulation for Mechanical Circulatory Support Devices: A Pilot Retrospective Study.

Volod O, Lam LD, Lin G, Kam C, Kolyouthapong K, Mac J, Mirocha J, Ambrose PJ, Czer LS, Arabia FA.

ASAIO J. 2017 Jan/Feb;63(1):24-31. doi: 10.1097/MAT.0000000000000445.

PMID:
27660902
44.

Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.

Jenks JD, Kumarasamy N, Ezhilarasi C, Poongulali S, Ambrose P, Yepthomi T, Devaraj C, Benson CA.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1181-4. doi: 10.5588/ijtld.15.0997.

PMID:
27510243
45.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5141-5. doi: 10.1128/AAC.00355-16. Print 2016 Sep.

46.

Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.

VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3891-6. doi: 10.1128/AAC.02943-15. Print 2016 Jul.

47.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

48.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

49.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

50.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

Supplemental Content

Loading ...
Support Center